Development of vaccines against superbugs: challenges and strategies

Quanming ZOU; Hao ZENG

doi:10.16016/j.1000-5404.201909029

您当前的位置：

首页 >

文章列表页 >

Development of vaccines against superbugs: challenges and strategies

Expert Reviews | 更新时间：2026-01-09

- Development of vaccines against superbugs: challenges and strategies
- Journal of Third Military Medical University Vol. 41, Issue 19, Pages: 1823-1826(2019)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)药学与检验医学系微生物与生化药学教研室，国家免疫生物制品工程技术研究中心
- 作者简介：
- 基金信息：
  
  the Major Project of Military Logistic Scientific Research(AWS16J029);the Confidential Special Program of Military Special Drugs(2016ZX09J16102-002);the General Program of National Natural Science Foundation of China(81571621)
- DOI：10.16016/j.1000-5404.201909029
  CLC： R378;R979.5
- Received：05 September 2019，
  
  Revised：2019-09-09，
  
  Published：15 October 2019
- 稿件说明：
移动端阅览
Quanming ZOU, Hao ZENG. Development of vaccines against superbugs: challenges and strategies[J]. Journal of Third Military Medical University, 2019, 41(19): 1823-1826.
DOI：

Quanming ZOU, Hao ZENG. Development of vaccines against superbugs: challenges and strategies[J]. Journal of Third Military Medical University, 2019, 41(19): 1823-1826. DOI： 10.16016/j.1000-5404.201909029.

摘要

超级细菌(superbugs)泛指那些对多种抗生素具有耐药性的细菌，专业术语是“多重耐药性细菌”。2017年，WHO列出严重威胁人类的12种耐药细菌清单，金黄色葡萄球菌、鲍曼不动杆菌、铜绿假单胞菌和肺炎克雷伯菌在清单中分别位列G

菌首位和G

菌前3位。因现在大部分的抗生素对它们已失去效力，全人类将面临难以承受的巨大挑战与威胁。疫苗是防控致病菌流行感染最佳的科学手段。我国科学家团队已研制国际首个靶标最多、效果最佳的金黄色葡萄球菌疫苗，正开展Ⅱ期临床试验。近20年来，欧美国家先后研发20余种超级细菌疫苗进行临床试验，但尚无一项成功。超级细菌疫苗研究面临巨大的挑战，如超级细菌致病机制不详，超级细菌疫苗如何在易感人群快速起效，超级细菌动物模型、临床流行病学基础数据和临床试验评价的关键技术及标准缺乏等均是目前超级细菌研究亟待解决的难题。我们建议今后的研究围绕以下几个方面进行:①建立保护性抗原表位大数据及高通量筛选新技术；②研究耐药菌疫苗快速起效机制及新技术；③开展超级细菌疫苗使用人群的免疫应答规律及特征研究；④建立成熟、稳定的超级细菌感染动物模型；⑤运用大数据、人工智能、基因组学等建立超级细菌流行病学大数据库和菌种资源库；⑥开展细菌疫苗的免疫保护机制及其核心指标的研究。

Abstract

Superbugs are broadly referred to the bacteria that are resistant to multiple antibiotics

and the special term is "multi-drug resistant bacteria". In 2017

WHO listed 12 antibiotic-resistant bacteria that can cause severe illness or death in humans as the global priority pathogens

including methicillin-resistant

Staphylococcus aureus

(MRSA)

Acinetobacter baumannii

Pseudomonas aeruginosa

and

Klebsiella pneumonia

. MRSA ranks the first among Gram-positive bacteria and the others take the top 3 among Gram-negative bacteria. Because most of antibiotics have lost their effectiveness to them

human beings have to face enormous challenges and threats that cannot be tolerated. Vaccine is one of the most effective preventive measures. Scientists from China have developed a unique effective vaccine against MRSA with the most multivalent and antigenic components in the world

which has been entered the phase Ⅱ clinical trial. In the past 2 decades

about 20 vaccines against superbugs were developed in the European and American countries

but none has demonstrated protection in human trials. The development of vaccine against superbugs is still an enormous challeng

e to scientist. There are some problems that need to be solved in the current studies concerning superbugs

such as their pathogenesis

how the vaccines work rapidly in susceptible populations

animal model for superbugs

basic data in clinical epidemiology and assessment for clinical trials

and other key techniques and standards. We suggest that future researches should be carried out in the following aspects: ① establishment of big data about protective antigen epitopes and high-throughput screening techniques; ② rapid onset mechanism and new technology of superbug vaccine; ③ rule and characteristics of immune responses of superbug vaccine; ④ establishment of a mature and stable animal model of superbug infection; ⑤ establishment of a database of superbug epidemiology and strains base on big data

artificial intelligence and genomics; ⑥ immune protection mechanisms and core indicators of superbug vaccines.

关键词

Keywords

references

WILLYARD C. The drug-resistant bacteria that pose the greatest health threats[J]. Nature, 2017, 543(7643): 15. DOI:10.1038/nature.2017.21550.

GALAR A, WEIL A A, DUDZINSKI D M, et al . Methicillin-resistant Staphylococcus aureus prosthetic valve endocarditis: pathophysiology, epidemiology, clinical presentation, diagnosis, and management[J ] . Clin Microbiol Rev, 2019, 32(2): e00041-e00018. DOI:10.1128/CMR.00041-18.

HORCAJADA J P, MONTERO M, OLIVER A, et al . Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections[J ] . Clin Microbiol Rev, 2019, 32(4): e00031-e00019. DOI:10.1128/CMR.00031-19.

HOOI J K Y, LAI W Y, NG W K, et al . Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis[J ] . Gastroenterology, 2017, 153(2): 420-429. DOI:10.1053/j.gastro.2017.04.022.

WEINER L M, WEBB A K, LIMBAGO B, et al . Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for diseasecontrol and prevention, 2011-2014[J ] . Infect Control Hosp Epidemiol, 2016, 37(11): 1288-1301. DOI:10.1017/ice.2016.174.

HU F P, GUO Y, ZHU D M, et al .Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014[J ] . Clin Microbiol Infect, 2016, 1:S9-14.DOI: 10.1016/j.cmi.2016.01.001.

邹全明, 石云.超级细菌疫苗研究进展[J].第三军医大学学报, 2016, 38(7): 663-668. DOI:10.16016/j.1000-5404.201601182.

ZOU Q M, SHI Y. Prospect for vaccines to prevent superbug infection[J]. J Third Mil Med Univ, 2016, 38(7): 663-668. DOI:10.16016/j. 1000-5404.201601182.

INOUE M, YONEMURA T, BABER J, et al . Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults[J ] . Hum Vaccin Immunother, 2018, 14(11): 2682-2691. DOI:10.1080/21645515.2018.1496764.

MISSIAKAS D, SCHNEEWIND O. Staphylococcus aureus vaccines: Deviating from the carol[J]. J Exp Med, 2016, 213(9): 1645-1653. DOI:10.1084/jem.20160569.

WESTRITSCHNIG K, HOCHREITER R, WALLNER G, et al . A randomized, placebo-controlled phase Ⅰ study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers[J ] . Hum Vaccin Immunother, 2014, 10(1): 170-183. DOI:10.4161/hv.26565.

O'BRIEN E C, MCLOUGHLIN R M. Considering the 'Alternatives' for next-generation anti-Staphylococcus aureus vaccine development[J]. Trends Mol Med, 2019, 25(3): 171-184. DOI:10.1016/j.molmed. 2018.12.010.

RAMÍREZ-ESTRADA S, BORGATTA B, RELLO J. Pseudomonas aeruginosa ventilator-associated pneumonia management[J]. Infect Drug Resist, 2016, 9: 7-18. DOI:10.2147/IDR.S50669.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Prospect for vaccines to prevent superbug infection

Related Author

邹全明

石云

Related Institution

No data

⁰